The British Medical Journal published a study from Denmark on May 10, 2012, linking vaginal rings like NuvaRing to as much as a 90% increased risk of blood clots over oral contraceptives. On June 14, 2012, the New England Journal of Medicine also published a Danish study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.
So far, the FDA has received over 1,000 reports of blood clot injury or death in patients using NuvaRing. On October 27, 2011 they released a report titled, “Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints,” which showed vaginal ring contraceptives could increase the risks of blood clots by as much as 56% over traditional birth control pills.
If you, or someone you know, has experienced adverse effects as a result of using Nuvaring®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturer of Nuvaring®.